INTRODUCTION: Colorectal cancer is the third most common malignancy in the developed countries, and about a quarter of people present with intestinal obstruction or perforation. Risk factors for colorectal cancer are mainly dietary and genetic. Overall 5-year survival is about 50%, with half of people having surgery experiencing recurrence of the disease. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for colorectal cancer? We searched: Medline, Embase, The Cochrane Library, and other important databases up to August 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 57 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adjuvant systemic chemotherapy, preoperative radiotherapy, and routine intensive follow-up.
INTRODUCTION:Colorectal cancer is the third most common malignancy in the developed countries, and about a quarter of people present with intestinal obstruction or perforation. Risk factors for colorectal cancer are mainly dietary and genetic. Overall 5-year survival is about 50%, with half of people having surgery experiencing recurrence of the disease. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for colorectal cancer? We searched: Medline, Embase, The Cochrane Library, and other important databases up to August 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 57 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adjuvant systemic chemotherapy, preoperative radiotherapy, and routine intensive follow-up.
Authors: Barry C Lembersky; H Samuel Wieand; Nicholas J Petrelli; Michael J O'Connell; Linda H Colangelo; Roy E Smith; Thomas E Seay; Jeffrey K Giguere; M Ernest Marshall; Andrew D Jacobs; Lauren K Colman; Atilla Soran; Greg Yothers; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: Anita Koushik; David J Hunter; Donna Spiegelman; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Eugenia E Calle; Eunyoung Cho; Gary E Fraser; Jo L Freudenheim; Charles S Fuchs; Edward L Giovannucci; R Alexandra Goldbohm; Lisa Harnack; David R Jacobs; Ikuko Kato; Vittorio Krogh; Susanna C Larsson; Michael F Leitzmann; James R Marshall; Marjorie L McCullough; Anthony B Miller; Pirjo Pietinen; Thomas E Rohan; Arthur Schatzkin; Sabina Sieri; Mikko J Virtanen; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shumin M Zhang; Stephanie A Smith-Warner Journal: J Natl Cancer Inst Date: 2007-09-25 Impact factor: 13.506
Authors: A M Stiggelbout; J C de Haes; R Vree; C J van de Velde; C M Bruijninckx; K van Groningen; J Kievit Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: M P Coleman; B Rachet; L M Woods; E Mitry; M Riga; N Cooper; M J Quinn; H Brenner; J Estève Journal: Br J Cancer Date: 2004-04-05 Impact factor: 7.640